"Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC" by Traci Hilton

Selected Works of Walter J. Urba, MD, PhD

Article

Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC

Journal for ImmunoTherapy of Cancer (2014)

Traci Hilton
Rachel Sanborn, Providence Portland Medical Center
Brian Boulmay, LSU Health Sciences Center New Orleans
Rui Li, Providence Portland Medical Center
Bradley Spieler, LSU Health Sciences Center New Orleans
Kyle Happel, LSU Health Sciences Center New Orleans
Christopher Paustian, Oregon Health & Science University
Tarsem Moudgil, Providence Portland Medical Center
Christopher Dubay, Oregon Health & Science University
Brenda Fisher, Providence Portland Medical Center
Eileen Mederos, LSU Health Sciences Center New Orleans
Augusto Ochoa, LSU Health Sciences Center New Orleans
Walter J Urba
Hong-Ming Hu, Southeast University
Bernard Fox, Oregon Health & Science University

Link

Disciplines

Publication Date

January 1, 2014

DOI

10.1186/2051-1426-2-S3-P249

Citation Information

Traci Hilton, Rachel Sanborn, Brian Boulmay, Rui Li, et al.. "Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC" Journal for ImmunoTherapy of Cancer Vol. 2 Iss. 2 (2014) p. 249
Available at: http://works.bepress.com/walter-urba/135/